Department of Biochemistry, Maharishi Markandeshwar College of Medical Sciences and Research (MMCMSR), Sadopur, Ambala, 134007, India.
School of Biotechnology, Jawaharlal Nehru University, New Delhi, 110067, India.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr;397(4):2055-2065. doi: 10.1007/s00210-023-02769-y. Epub 2023 Oct 14.
Recent years have witnessed the rise of more recent pandemic outbreaks including COVID-19 and monkeypox. A multinational monkeypox outbreak creates a complex situation that necessitates countermeasures to the existing quo. The first incidence of monkeypox was documented in the 1970s, and further outbreaks led to a public health emergency of international concern. Yet as of right now, neither vaccines nor medicines are certain to treat monkeypox. Even the inability of conducting human clinical trials has prevented thousands of patients from receiving effective disease management. The current state of the disease's understanding, the treatment options available, financial resources, and lastly international policies to control an epidemic state are the major obstacles to controlling epidemics. The current review focuses on the epidemiology of monkeypox, scientific ideas, and available treatments, including potential monkeypox therapeutic methods. As a result, a thorough understanding of monkeypox literature will facilitate in the development of new therapeutic medications for the prevention and treatment of monkeypox.
近年来，包括 COVID-19 和猴痘在内的新发传染病疫情有所增加。多国猴痘疫情爆发，情况复杂，需要对现状采取对策。首例猴痘病例记录于 20 世纪 70 年代，进一步的疫情爆发导致国际关注的突发公共卫生事件。然而，到目前为止，既没有疫苗也没有药物可以确定治疗猴痘。即使无法进行人体临床试验，也阻止了数千名患者接受有效的疾病管理。目前对疾病的认识、现有的治疗选择、财政资源，以及最后控制传染病状态的国际政策，是控制传染病的主要障碍。目前的综述重点关注猴痘的流行病学、科学思路和现有治疗方法，包括潜在的猴痘治疗方法。因此，对猴痘文献的深入了解将有助于开发预防和治疗猴痘的新治疗药物。
